The authors regret that, during the preparation of our published manuscript “Combined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors” [1], we submitted an incorrect version of Figure 2. Thus, Figure 2 should be replaced with the following figure (Figure 1).
Figure 1.
The mRNA expression levels of genes associated with hepatic fibrogenesis in HSC-T6 cells treated with a combination of taurine, EGCG and genistein. Semi-quantitative PCR data are shown for cells treated with a combination of taurine, EGCG and genistein in varying doses. The relative mRNA expression levels of TGF-β1 (A), Col-I (B), TIMP-1 (C), TIMP-2 (D), and MMP-2 (E) are presented; the upper panels show representative pictures of agarose gels and the lower panels show relative quantification of mRNA expression levels in (I) untreated control cells, or cells treated with (II) 0.015 mg/mL taurine, 0.0175 mg/mL EGCG and 0.0035 mg/mL genistein, (III) 0.03 mg/mL taurine, 0.035 mg/mL EGCG and 0.007 mg/mL genistein, or (IV) 0.06 mg/mL taurine, 0.07 mg/mL EGCG and 0.014 mg/mL genistein. (M) Marker. Data are presented as the mean ± S.E.; * p < 0.05 vs. group I (untreated control).
The correction does not change the scientific conclusions of the article in any way. The authors apologize for any confusion this error may have caused to the readers.
Conflicts of Interest
The authors declare no conflict of interest.
Reference
- Li, Y.; Luo, Y.; Zhang, X.; Lin, X.; He, M.; Liao, M. Combined Taurine, Epigallocatechin Gallate and Genistein Therapy Reduces HSC-T6 Cell Proliferation and Modulates the Expression of Fibrogenic Factors. Int. J. Mol. Sci. 2013, 14, 20543–20554. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).